18-10-2-1　ⓔ文献

  1. Weglage J, Bick U, et al: Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence. Neuropediatrics, 1997; 28: 239–240.

  2. Bick U, Ullrich K, et al: White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur J Pediatr, 1993; 152: 1012–1020.

  3. Bick U, Fahrendorf G, et al: Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging. Eur J Pediatr, 1991; 150: 185–189.

  4. ten Hoedt AE, de Sonneville LM, et al: High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double–blind, placebo–controlled, crossover trial. J Inherit Metab Dis, 2011; 34: 165–171.

  5. MacLeod EL, Ney DM: Nutritional management of phenylketonuria. Ann Nestle Eng, 2010; 68; 58–69.

  6. Markham A: Pegvaliase: First Global Approval. BioDrugs, 2018; 32: 391–395.